Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lacticaseibacillus casei AMBR2
- Development stage
- Phase 1
- Lead developer
- University of Antwerp
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intranasal, Topical
01
Overview
Lacticaseibacillus casei AMBR2 is a specific strain of probiotic bacteria developed as a live biotherapeutic product (LBP) for upper respiratory tract (URT) health. Originally isolated from the human nasopharynx, it is being investigated for its ability to restore epithelial barrier integrity and provide antiviral protection. Its primary mechanism of action in the nasal mucosa is mediated through the activation of Toll-like receptor 2 (TLR2), which leads to the reorganization of tight junction proteins such as occludin and zonula occludens-1 (ZO-1), effectively repairing barrier defects caused by inflammatory cytokines like IL-4. Furthermore, AMBR2 has demonstrated the capacity to induce interferon regulatory pathways and provide broad-acting inhibition against respiratory viruses, including influenza A/B, respiratory syncytial virus (RSV), and coronaviruses (HCoV-229E). It is primarily developed for applications in chronic rhinosinusitis with nasal polyps (CRSwNP) and as a topical throat spray for preventing or treating respiratory viral infections.
- Other names
- L. casei AMBR2Lactobacillus casei AMBR2
02
Targets
TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on lacticaseibacillus casei AMBR2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lacticaseibacillus casei AMBR2.